NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

VolverVolver

Resultados 72 resultados LastUpdate Última actualización 27/05/2020 [15:13:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 3 nextPage   por página


THIAZOLOPYRIMIDINE HETEROCYCLIC COMPOUND, COMPOSITION AND USE THEREOF IN TREATMENT OF LUMPHOCYTIC LEUKEMIA

NºPublicación: WO2020098466A1 22/05/2020

Solicitante:

UNIV DALIAN MEDICAL [CN]
THE FIRST AFFILIATED HOSPITAL OF DALIAN MEDICAL UNIV [CN]

CN_109265469_A

Resumen de: WO2020098466A1

The present invention provides a thiazolopyrimidine heterocyclic compound, a composition and use thereof in preparation of drugs for treatment of lymphocytic leukemia. The thiazolopyrimidine heterocyclic compound is specifically a compound as represented in general formula (I), respective substituent groups in general formula (I) are defined in the specification. The present invention further provides a use of the compound as represented in general formula (I) or pharmaceutically acceptable salts thereof or of a pharmaceutical composition containing same in treatment of tumor diseases by means of inhibiting JAK3 tyrosine kinase, in particular in preparation of drugs for treatment of Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma or chronic lymphocytic leukemia.

traducir

COMBINATION THERAPIES FOR MULTIPLE MYELOMA

NºPublicación: WO2020102226A1 22/05/2020

Solicitante:

NANTCELL INC [US]

Resumen de: WO2020102226A1

Compositions and methods are provided to treat and prevent cancers, such as myelomas, and include adoptive cell therapies in combination with an IL-15 superagonist and one or more chemotherapeutic agents.

traducir

METHODS OF DOSING ENGINEERED T CELLS FOR THE TREATMENT OF B CELL MALIGNANCIES

NºPublicación: WO2020102770A1 22/05/2020

Solicitante:

JUNO THERAPEUTICS INC [US]

Resumen de: WO2020102770A1

Provided are methods for treatment and uses involving the administration of doses of engineered T cells for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The engineered cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL). In some embodiments, the subject is within a particular range of age, such as subjects that are 25 years or less of age, such as pediatric subjects.

traducir

BISPECIFIC ANTIBODIES DIRECTED AGAINST HUMAN 90K AND EITHER ENDOSIALIN OR HER3

NºPublicación: WO2020099235A1 22/05/2020

Solicitante:

MEDIAPHARMA S R L [IT]
PHARMAMAB SRL [IT]
PHARMAGO SRL [IT]

Resumen de: WO2020099235A1

The present invention relates to a bispecific antibody, that specifically binds to both 90K and one of Endosialin and HER-3, a production method therefor, and novel usethereof in the treatment of hyperproliferative diseases such as tumors and metastases thereof. In particular, the invention relates to the use of bispecific antibodies able to inhibit the adhesive processes of tumor cells and the angiogenesis in tumors such as breast cancer, ovarian cancer, lung cancer, gastrointestinal cancer, melanoma, lymphoma and other tumors.

traducir

CRYSTALLINE FORMS OF BRIGATINIB

NºPublicación: WO2020099483A1 22/05/2020

Solicitante:

SANDOZ AG [CH]

Resumen de: WO2020099483A1

The present invention relates to new crystalline forms of 5-chloro-N4-[2- (dimethylphosphoryl)phenyl]-N2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1- yl]phenyl]pyrimidine-2, 4-diamine (also referred to as "brigatinib"), in particular to a crystalline hydrate system and to crystalline acid addition salts of brigatinib, and methods for preparing same. The invention also refers to a pharmaceutical composition comprising the said hydrate system or said acid addition salts of brigatinib. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of anaplastic lymphoma kinase (ALK) positive metastatic non-small cell lung cancer (NSCLC) and other diseases.

traducir

SYNERGISTIC COMBINATIONS OF METHIONINE DEPLETION AGENTS AND IMMUNE CHECKPOINT MODULATORS

NºPublicación: WO2020099592A1 22/05/2020

Solicitante:

ERYTECH PHARMA [FR]

Resumen de: WO2020099592A1

The invention concerns a pharmaceutical composition, kit or fixed-dose combination comprising a methionine depletion agent (MDA), and an anti-cancer immune modulator (ACIM), for use in the treatment of a disease or condition in a subject or patient in need of treatment thereof. Synergic combinations are provided. Cancer may be for example acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), pancreatic cancer, gastric cancer, colorectal cancer, prostate cancer, ovarian cancer, brain cancer, head and neck cancer or breast cancer.

traducir

GLYCOPOLYSIALYLATION OF BLINATUMOMAB

NºPublicación: WO2020099513A1 22/05/2020

Solicitante:

LIPOXEN TECH LIMITED [GB]

Resumen de: WO2020099513A1

A composition comprising a population of polysaccharide-blinatumomab conjugates, wherein the polysaccharide is covalently linked to the blinatumomab. A method of increasing the efficacy of a therapeutic agent in the treatment of B-cell precursor acute lymphoblastic leukemia (ALL), wherein the therapeutic agent is a PSA-drug conjugate, wherein the conjugate comprises PSA covalently linked to blinatumomab, and wherein the PSA of the conjugate binds to DNA and histones of NET extracellular fibrils.

traducir

Extended interval dosing of natalizumab

NºPublicación: AU2018355447A1 21/05/2020

Solicitante:

BIOGEN MA INC [US]

WO_2019084335_A1

Resumen de: AU2018355447A1

Provided herein, in some embodiments, are methods for reducing the risk of developing progressive multifocal leukemia in patients undergoing natalizumab therapy by switching to an extended interval dosing (EID) schedule.

traducir

DRUG FORMULATIONS

NºPublicación: US2020155588A1 21/05/2020

Solicitante:

ASTEX PHARMACEUTICALS INC [US]

ES_2702495_T3

Resumen de: US2020155588A1

The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumours using the formulations are described.

traducir

7-SITE SUBSTITUTED PYRROLE TRIAZINE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PREPARATION METHOD THEREOF AND USES THEREOF

NºPublicación: US2020157110A1 21/05/2020

Solicitante:

SHANGHAI INST MATERIA MEDICA CAS [CN]

Resumen de: US2020157110A1

The present disclosure relates to 7-substituted pyrrolo[2,1-f][1,2,4]triazine compounds or pharmaceutically acceptable salts thereof, and preparation methods and uses thereof. These compounds show good PI3K inhibitory activity, can effectively inhibit the activity of PI3K kinase, and has significant enhancement and improvement of pharmacokinetic properties, such as bioavailability, due to the introduction of the 7-position group; furthermore, the compounds of the present disclosure exhibit an unpredictable high selectivity and strong inhibitory activity on PI3Kδ, and thus these compounds can be used for treating diseases related to PI3K pathway, especially for anti-cancer or for the treatment of tumors, leukemias and autoimmune diseases. After further optimizing and screening, the compounds are expected to be developed into a new type of anti-tumor drugs.

traducir

NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, IN PARTICULAR CHRONIC LYMPHOID LEUKEMIA (CLL)

NºPublicación: US2020157148A1 21/05/2020

Solicitante:

IMMATICS BIOTECHNOLOGIES GMBH [DE]

US_2019284233_A1

Resumen de: US2020157148A1

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

traducir

TARGETING OF ANAPLASTIC LYMPHOMA KINASE IN SQUAMOUS CELL CARCINOMA

NºPublicación: US2020157637A1 21/05/2020

Solicitante:

UNIV TEXAS [US]

WO_2018217849_A1

Resumen de: US2020157637A1

Methods for identifying patients with high risk (progression, invasion, metastasis) squamous cell carcinoma using methylation and/or expression assays are disclosed. Also provided are methods of treating such high risk cancers with ALK inhibitors combined with anti-EGFR based therapies, as the data show a correlation between ALK hypomethylation and EGFR activation.

traducir

Exo-aza spiro inhibitors of menin-MLL interaction

NºPublicación: AU2018389145A1 21/05/2020

Solicitante:

JANSSEN PHARMACEUTICA NV [BE]

WO_2019120209_PA

Resumen de: AU2018389145A1

Provided are compounds of Formula (I), pharmaceutical compositions comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

traducir

BROMODOMAIN AND EXTRA-TERMINAL PROTEIN INHIBITOR COMBINATION THERAPY

NºPublicación: US2020155539A1 21/05/2020

Solicitante:

CELGENE QUANTICEL RES INC [US]

JP_2019535682_A

Resumen de: US2020155539A1

The present disclosure relates generally to compositions and methods of treating neoplastic diseases or cancers, such as glioblastoma and non-Hodgkin's lymphomas, or other cancers in which the subject suffers from an advanced solid tumor, comprising a combination of, or administering a combination of, a bromodomain and extra-terminal protein (BET) inhibitor and at least one chemotherapeutic agent, which does not inhibit BET directly. The BET inhibitor/chemotherapeutic agent combination, or combination therapy, can yield synergistic effects, thereby increasing the effectiveness of the cancer treatment as compared with the administration of either the BET inhibitor or the chemotherapeutic agent alone.

traducir

INHIBITOR OF HISTONE DEACETYLASE 6 IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) AND OTHER NEOPLASIA WITH HIGH EXPRESSION OF NOTCH-3

NºPublicación: US2020155549A1 21/05/2020

Solicitante:

ST ONCOLOGICO VENETO IOV IRCCS [IT]

WO_2019021239_A1

Resumen de: US2020155549A1

A method for treating T-cell acute lymphoblastic leukemia (T-ALL) and other neoplasia with high expression of Notch3 is provided.

traducir

TARGETING LYSINE DEMETHYLASES (KDMS) AS A THERAPEUTIC STRATEGY FOR DIFFUSE LARGE B-CELL LYMPHOMA

NºPublicación: US2020155526A1 21/05/2020

Solicitante:

CHILDRENS MEDICAL CT CORP [US]

WO_2018222831_A1

Resumen de: US2020155526A1

Described herein are methods for treating cancer. Aspects of the invention relate to administering to a subject a compound that targets a KDM4 or KDM5 family member, wherein the subject has at least one mutation in an epigenetic modifier selected from the group consisting of: EZH2, KMT2D, CREBPP, and EP300. In one embodiment, the compound is J1B04. Another aspect of the invention relates to a method of treating diffuse large B-cell lymphoma.

traducir

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA BY ERADICATING LEUKEMIC STEM CELLS

NºPublicación: WO2020094609A1 14/05/2020

Solicitante:

INST NAT SANTE RECH MED [FR]
UNIV TOULOUSE 3 PAUL SABATIER [FR]
CT HOSPITALIER UNIVERSITAIRE TOULOUSE [FR]

Resumen de: WO2020094609A1

After intensive chemotherapy, the emergence of cells with drug resistant and/or stem cell features might explain frequent relapses and the poor outcome of patients with acute myeloid leukemia (AML). Herein the inventors first uncovered that the adrenomedullin receptor CALCRL is overexpressed in AML patients comparing with normal cells and preferentially in the immature CD34+CD38- compartment. Then they demonstrated its role in the maintenance of leukemic stem cell function in vivo. Moreover, CALCRL depletion strongly affected leukemic growth in xenograft models and sensitized to chemotherapeutic agent cytarabine in vivo. Accordingly, the inventors showed that ADM-CALCRL axis drove cell cycle, DNA integrity, and high OxPHOS status of chemoresistant AML stem cells in an E2F1- and BCL2- dependent manner. Furthermore, CALCRL depletion sensitizes cells to cytarabine and its expression predicted the response to chemotherapy in vivo in mice. Further, using the combination of limiting dilution assays, single-cell RNA-seq analysis of primary AMF samples at diagnosis and relapse and before and after transplantation in NSG mice, the inventors revealed the pre-existence of a chemoresistant leukemic stem cell sub-population harboring a CALCRL-driven gene signature. Finally the inventors strongly demonstrated that chemoresistant LSC are dependent for CALCRL. All of these data highlight the critical role of CALCRL in stem cell survival, proliferation and metabolism and identify this recepto

traducir

COMBINATION OF PRMT5 INHIBITORS AND BCL-2 INHIBITORS

NºPublicación: WO2020094712A1 14/05/2020

Solicitante:

GLAXOSMITHKLINE IP DEV LTD [GB]

Resumen de: WO2020094712A1

The present invention relates to a combination of a protein arginine methyltransferase 5 (PRMT5) inhibitor and a B cell lymphoma 2 (BCL-2) inhibitor and the use of this combination in the treatment of cancer. In specific instances of the invention the PRMT5 inhibitor may be a compound of Formula (I).

traducir

USE OF MRNA ENCODING OX40L TO TREAT CANCER IN HUMAN PATIENTS

NºPublicación: WO2020097409A2 14/05/2020

Solicitante:

MODERNATX INC [US]

Resumen de: WO2020097409A2

The disclosure features methods for treating ovarian cancer, as well as other cancers such as solid tumors, lymphomas and epithelial origin cancers, by administering mRNA encoding an OX40L polypeptide. The disclosure also features compositions for use in the methods. The disclosure also features combination therapies, such as use of mRNA encoding an OX40L polypeptide in combination with a checkpoint inhibitor, such as an anti-PD-Ll antibody.

traducir

SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN

NºPublicación: WO2020097577A1 14/05/2020

Solicitante:

PRELUDE THERAPEUTICS INCORPORATED [US]

US_2020148705_A1

Resumen de: WO2020097577A1

The disclosure is directed to compounds of Formula I (I) Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.

traducir

Treatment of CD20-positive B-cell lymphoma with obituzumab

NºPublicación: AU2018303836A1 14/05/2020

Solicitante:

HOFFMANN LA ROCHE [CH]

JP_2019528282_A

Resumen de: AU2018303836A1

The present disclosure relates to administration speed of obinutuzumab.

traducir

Method for treating acute myeloid leukemia

NºPublicación: AU2018355886A1 14/05/2020

Solicitante:

BIONOMICS LTD [AU]

WO_2019079848_A1

Resumen de: AU2018355886A1

The present invention relates to a method for the treatment of acute myeloid leukemia (AML) with medicaments useful for same. The medicaments can be pharmaceutical compositions or kits comprising compounds of the presently-described formula (I) or a salt, solvate or prodrug thereof. Specific compounds of the invention include 2-methyl-7-hydroxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran which is also known as BNC105 and disodium 6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzofuran-7-yl phosphate which is also known as BNC105P.

traducir

Feline leukemia virus vaccine

NºPublicación: AU2018358077A1 14/05/2020

Solicitante:

INTERVET INT BV [NL]

Resumen de: AU2018358077A1

The present invention provides a vaccine for feline leukemia virus and methods of making and using the vaccine alone, or in combinations with other protective agents.

traducir

DISCOVERY OF A SOMATIC MUTATION IN MYD88 GENE IN LYMPHOPLASMACYTIC LYMPHOMA

NºPublicación: US2020149114A1 14/05/2020

Solicitante:

DANA FARBER CANCER INST INC [US]

US_2014249142_A1

Resumen de: US2020149114A1

Diagnostic assays for facilitating the diagnosis of lymphoplasmacytic lymphoma (LPL) are provided. The method comprises assessing a biological sample of the subject for the presence of a mutation at position 38182641 in chromosome 3p22.2, wherein presence of the mutation is indicative that the subject has LPL. Also, provided are targeted therapies, methods for monitoring the progression or recurrence of LPL, and a sensitive and inexpensive real-time allele specific polymerase chain reaction assay for reliable and quantitative assessments of the mutation.

traducir

INFLAMMASOME ACTIVATION IN MYELODYSPLASTIC SYNDROMES

Nº publicación: US2020150118A1 14/05/2020

Solicitante:

H LEE MOFFITT CANCER CENTER AND RES INSTITUTE INC [US]

Resumen de: US2020150118A1

Disclosed are methods for diagnosing a myelodysplastic syndrome (MDS) in a subject. In some embodiments, the method involves assaying a sample from the subject to detect inflammasome activation, wherein an increase in inflammasome activation in the sample compared to a control is an indication of MDS in the subject. The disclosed methods can further involve treating the subject for MDS if an increase in inflammasome activation is detected.

traducir

Página1 de 3 nextPage por página

punteroimgVolver